Table 3.
Associations between two tagSNPs and lung cancer risk stratified by smoking status in eight lung cancer GWASs
| Study | Case | Control | rs3769201 C > T | rs722864 G > A | ||
|---|---|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | |||
| Ever smokers | ||||||
| IARC | 2367 | 2508 | 0.87 (0.79, 0.96) | 0.005 | 0.88 (0.79, 0.98) | 0.017 |
| Toronto | 236 | 272 | 1.04 (0.75, 1.43) | 0.820 | 1.05 (0.75, 1.48) | 0.770 |
| GLC | 433 | 258 | 0.97 (0.72, 1.31) | 0.844 | 0.97 (0.71, 1.32) | 0.835 |
| Harvard | 892 | 809 | 0.97 (0.82, 1.15) | 0.733 | ||
| MDACC | 1150 | 1134 | 0.91 (0.79, 1.06) | 0.218 | 0.90 (0.78, 1.05) | 0.179 |
| ATBC | 1732 | 1270 | 0.88 (0.77, 1.00) | 0.048 | 0.90 (0.78, 1.04) | 0.143 |
| CPSII | 600 | 383 | 0.79 (0.62, 1.00) | 0.051 | 0.86 (0.68, 1.10) | 0.241 |
| EAGLE | 1767 | 1339 | 0.90 (0.80, 1.02) | 0.107 | 0.90 (0.79, 1.02) | 0.104 |
| PLCO | 1243 | 1344 | 0.90 (0.77, 1.03) | 0.133 | 0.86 (0.74, 1.00) | 0.045 |
| Overall | 10420 | 9317 | 0.90 (0.85, 0.94) | 1.79E-05 | 0.89 (0.85, 0.94) | 5.58E-05 |
| Never smokers | ||||||
| IARC | 159 | 1253 | 0.94 (0.70, 1.25) | 0.663 | 0.95 (0.70, 1.31) | 0.769 |
| Toronto | 95 | 217 | 0.95 (0.61, 1.50) | 0.832 | 0.89 (0.55, 1.44) | 0.642 |
| GLC | 35 | 220 | 1.15 (0.61, 2.18) | 0.663 | 1.16 (0.59, 2.29) | 0.675 |
| Harvard | 92 | 161 | 1.03 (0.66, 1.60) | 0.896 | ||
| CPSII | 86 | 275 | 1.03 (0.67, 1.60) | 0.880 | 1.09 (0.70, 1.70) | 0.710 |
| EAGLE | 138 | 634 | 1.07 (0.77, 1.50) | 0.675 | 1.00 (0.70, 1.43) | 0.987 |
| PLCO | 126 | 470 | 0.76 (0.49, 1.17) | 0.208 | 0.72 (0.46, 1.12) | 0.145 |
| Overall | 731 | 3230 | 0.97 (0.84, 1.13) | 0.725 | 0.95 (0.80, 1.12) | 0.520 |
GWAS: genome-wide association study; AD, adenocarcinoma; SC, squamous cell carcinoma; OR: odds ratio; CI: confidence interval; NCI GWAS includes four sub-studies: the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC), the Cancer Prevention Study II Nutrition Cohort (CPS-II), the Environment and Genetics in Lung Cancer Etiology (EAGLE), and the Prostate, Lung, Colon, Ovary Screening Trial (PLCO).